Showing 1 - 12 results of 12 for search 'Zofia Piotrowska', query time: 0.04s
Refine Results
-
1
-
2
-
3
Application of Erythromycin and/or <i>Raoultella</i> sp. Strain MC3 Alters the Metabolic Activity of Soil Microbial Communities as Revealed by the Community Level Physiological Pro... by Mariusz Cycoń, Anna Markowicz, Tomasz J. Wąsik, Zofia Piotrowska-Seget
Published 2020-11-01
Article -
4
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer by Jiyun Lee, Zofia Piotrowska, Ross Soo, Byoung Chul Cho, Sun Min Lim
Published 2022-12-01
Article -
5
Comparison of Two Inoculation Methods of Endophytic Bacteria to Enhance Phytodegradation Efficacy of an Aged Petroleum Hydrocarbons Polluted Soil by Małgorzata Pawlik, Tomasz Płociniczak, Sofie Thijs, Isabel Pintelon, Jaco Vangronsveld, Zofia Piotrowska-Seget
Published 2020-08-01
Article -
6
-
7
-
8
Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY by Jill Feldman, MA, Ivy Elkins, MBA, Zofia Piotrowska, MD, Bellinda L. King-Kallimanis, PhD, Tendai Chihuri, MD, Carly Johnson, BS, Alecia Clary, PhD, Teri Kennedy, MA, Upal Basu Roy, PhD, MPH
Published 2025-03-01
Article -
9
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC by Alissa J. Cooper, MD, Alona Muzikansky, MA, Jochen Lennerz, MD, PhD, Farhaana Narinesingh, M.B.B.S., Mari Mino-Kenudson, MD, Yin P. Hung, MD, PhD, Zofia Piotrowska, MD, MHS, Ibiayi Dagogo-Jack, MD, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jessica J. Lin, MD, Rebecca S. Heist, MD, MPH
Published 2022-09-01
Article -
10
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience by A.J. Piper-Vallillo, MD, Julia K. Rotow, MD, Jacqueline V. Aredo, MD, Khvaramze Shaverdashvili, MD, PhD, Jia Luo, MD, Jennifer W. Carlisle, MD, Hatim Husain, MD, Alona Muzikansky, MA, Rebecca S. Heist, MD, Deepa Rangachari, MD, Suresh S. Ramalingam, MD, Heather A. Wakelee, MD, Helena A. Yu, MD, Lecia V. Sequist, MD, Joshua M. Bauml, MD, Joel W. Neal, MD, PhD, Zofia Piotrowska, MD, MHS
Published 2022-06-01
Article -
11
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study by Jingran Ji, MD, Jacqueline V. Aredo, MD, MS, Andrew Piper-Vallillo, MD, Laura Huppert, MD, Julia K. Rotow, MD, Hatim Husain, MD, Susan Stewart, PhD, Rosemary Cobb, BS, Heather A. Wakelee, MD, Collin M. Blakely, MD, PhD, Melisa L. Wong, MD, MAS, Matthew A. Gubens, MD, MS, Mohammad H. Madani, MD, Subba R. Digumarthy, MD, Caroline McCoach, MD, PhD, Zofia Piotrowska, MD, MHS, Joel W. Neal, MD, PhD, Jonathan W. Riess, MD, MS
Published 2023-03-01
Article -
12
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study by Leou Ismael Banla, MD, PhD, Alice Tzeng, MD, PhD, John P. Baillieul, Melin J. Kandekhar, MD, PhD, Kelly J. Fitzgerald, MD, PhD, Jaclyn LoPiccolo, MD, PhD, Holly A. Poitras, Daniel E. Soto, MD, Julia K. Rotow, MD, Lisa Singer, MD, PhD, Henning Willers, MD, David E. Kozono, MD, PhD, Pasi A. Janne, MD, PhD, Raymond H. Mak, MD, Zofia Piotrowska, MD, Florence K. Keane, MD, Benjamin H. Kann, MD
Published 2023-10-01
Article